Two regulatory events define the billing environment heading into year-end. On October 5, 2026, CMS, the Department of Labor, and the Treasury Department jointly finalized the Transparency in Coverage (TiC) Final Rule (CMS 9882-F) — the most significant revision to machine-readable pricing rules since they took effect in July 2022. The rule takes effect December 5, 2026, with data requirements phasing in through 2027. And separately, the CY 2027 Medicare Physician Fee Schedule final rule is on track for release in mid-November, locking in the conversion factor and hundreds of coding policy decisions that practices have been modeling against the July proposal.
The TiC rule primarily governs what payers must publish, but its downstream effects land on practices: when the rate file a payer posts is wrong or outdated, referral decisions, out-of-network disputes, and patient cost estimates are all built on bad data. The key changes:
| Change | Old requirement | New requirement |
|---|---|---|
| Reporting frequency | Monthly | Quarterly |
| File location indicator | Not required | Plain-text file at website root pointing to MRF location |
| “Ghost rates” | No explicit standard | Must reflect actual paid rates; executive attestation required |
| Out-of-network data | Limited | Expanded OON pricing information required |
| Prescription drug files | Voluntary | Schema development begins November 2026; full requirement follows |
The “ghost rate” problem has been the biggest practical failure of the original rules: insurers published negotiated rates that looked real but did not reflect actual payments, either because contracts had changed or because the file included rates for providers who had never treated an insured patient. The new attestation requirement — requiring a plan executive to certify the data — is the mechanism CMS is using to force accountability. Practices that see systematic gaps between what a payer’s MRF says it pays and what it actually remits now have a documented accuracy standard to cite in disputes.
A practice that runs a competitive market analysis using payer MRFs today is likely working from stale or incorrect data. The December 5 effective date gives payers 57 days to begin correcting their files. The first quarterly submission under the new standard falls in early 2027. Build any rate benchmarking or payer negotiation work on the assumption that the first accurate file won’t be available until Q1–Q2 2027.
The July proposed rule contained four decisions that affect day-to-day billing for most practices and that will be locked in by the November final rule:
With federal funding expiring December 11 and the fee schedule final rule expected in November, the last six weeks of 2026 are the highest-density regulatory period practices will face before the January 1, 2027 go-live date for electronic prior authorization, the GLOBE model, and a new conversion factor. Build your 2027 budget line for Medicare revenue before the final rule lands, and revise it within 48 hours of publication.
Medicare open enrollment opens October 15 — six days from today — and runs through December 7. Your front-desk staff will be answering benefit questions in the middle of two parallel payer shifts: UnitedHealthcare’s October 1 prior authorization removals are now in their second week, and the federal electronic prior authorization API deadline is 84 days away.
UnitedHealthcare’s October 1 change removed prior authorization requirements on approximately 1,700 codes across commercial, Medicare Advantage, Community Plan, Individual Exchange, and Oxford plan lines. The affected clinical areas include cardiology imaging and interventional procedures, oncology, orthopedics, genetic and lab testing, chiropractic, and physical and occupational therapy. For practices that saw repeated PA-related claim delays in these categories through September, last week’s claims should now be cleaner on the prior-auth front.
Two cautions apply. First, removing PA does not remove all claim review: UHC retains post-payment review rights, and a code removed from PA may still trigger concurrent or retrospective utilization management. Second, plan-level variants exist — the authorization requirement for a specific code may differ across Oxford vs. a commercial UHC plan vs. a Medicare Advantage product. Verify each line on the payer’s official code list, not the summary coverage. Fidelis Care also updated its prior authorization requirements effective October 1 per its October 2026 provider bulletin.
As of January 1, 2027, Medicare Advantage plans, Medicaid managed care, and CHIP managed care organizations subject to CMS-0057-F must support the Prior Authorization API — a FHIR-based electronic connection that lets EHR and practice management systems send and receive prior authorization requests without navigating individual payer portals. 61% of practices currently access seven or more payer portals every week (MGMA); the API is designed to collapse that to a single workflow.
The rule requires the payer to build the API; it does not require the provider to use it. A practice whose EHR or clearinghouse has integrated the API by January 1 gets the benefit automatically. Ask your vendor directly about their timeline.
Effective October 1, 2026, at least one state (SB 63, signed April 17, 2026) bars health insurers from making coverage determinations based solely on AI and requires disclosure to providers when AI is used in a utilization review decision. The law reflects a growing legislative response to documented cases of automated claim denials upheld without individual clinical review. Similar proposals are active in several additional states. The federal equivalent — a proposed CMS rule requiring disclosure of AI use in coverage decisions for Medicare Advantage plans — remains pending.
Before October 15, prepare a one-page internal reference card listing (a) which payer plans in your market are exiting for 2027, (b) which prior authorization codes UHC removed from your highest-volume categories, and (c) when your clearinghouse or EHR vendor plans to support the January 1 electronic PA API. Give it to both your scheduling team and your billing team — open enrollment questions start this week.
On October 6, 2026, HFMA hosted a virtual session on determining which revenue cycle work suits traditional automation, agentic AI, or human expertise. The distinction matters because the tools work differently and fail differently — and the spread between organizations that have implemented AI and those that have not is widening fast.
The October 6 framework positions three tiers of automation against the revenue cycle workflow:
The Guidehouse/HFMA survey numbers reflect a real split: the 78% using automation skews heavily toward health systems with larger IT budgets and vendor contracts; the 59% who haven’t implemented are disproportionately smaller practices and independent groups.
MGMA’s IT chief Julia Rosen offered a concrete starting point for practices new to AI: begin in the revenue cycle, not in clinical AI. Denial prediction and coding support are lower regulatory risk than ambient documentation, have faster ROI, and typically live in software the practice already pays for. The guidance echoes a Guidehouse/HFMA theme: the first AI win is usually unlocking a feature inside an existing contract, not buying a new product.
The 78%/59% data point reflects a measurement problem: organizations that have turned on a single automation feature in their clearinghouse often report “yes” to automation adoption. Implementation maturity matters more than adoption rate. Before benchmarking your AI posture against market numbers, count how many workflows in your existing vendor stack are actually active vs. licensed-but-dormant.
The October 1 ICD-10 changeover is now in its second week. Payers typically take 30 to 60 days after a code set update before their edit libraries fully reflect the new files — which means the first wave of denials attributable to the new codes is landing now, and a second wave may still be coming.
| Issue | What to look for | Resolution |
|---|---|---|
| Deleted code still active in favorites | Rejection citing invalid code on claims dated October 1+ | Replace with valid FY 2027 code; audit favorites list |
| NCCI v32.3 new bundle | Denial citing bundling that did not exist in September | Check if modifier is appropriate; review NCCI edit file |
| MUE unit limit change | Unit-limit denial on a code whose MUE changed October 1 | Verify new MUE; split encounters if clinically appropriate |
| Payer edit library lag | Claim accepted in September, rejected in October | Resubmit after 30 days or call payer for manual override |
One of the highest-impact changes for practices running genetic counseling, oncology, GI, or molecular pathology workflows: FY 2027 introduced dedicated ICD-10-CM codes for Lynch syndrome, familial BRCA1/BRCA2 variants, and Li-Fraumeni syndrome — syndromes that previously shared a single “genetic susceptibility to malignant neoplasm” code. The new codes carry their own coverage and medical-necessity rules. A claim using the old unspecified code for a service that now has a specific code available will likely face denial or a documentation request.
The specificity also matters for NCD-governed lab services: any molecular or genetic test tied to a hereditary cancer syndrome diagnosis should now use the specific code to satisfy the LCD/NCD diagnosis pairing.
The October 8, 2026 MLN Connects edition published updates to the Remittance Advice Remark Codes (RARC) and Claim Adjustment Reason Codes (CARC) — the two-code combination that explains why Medicare denied or adjusted a claim. Any practice using automated denial triage that maps RARC/CARC combinations to workflow routing needs to update its crosswalk. The MLN also reminded providers to confirm their HETTS EDI Enrollment email address by December 1, 2026.
Pull all claims submitted October 1 or later and filter for denials that did not appear in September. Group by RARC/CARC pair, then by CPT code. Any cluster involving a code that changed in the October 1 update is a systemic issue — fix the root cause in your charge master or encoder before resubmitting the batch.
HFMA’s 2026 Revenue Cycle Benchmark Report, drawn from 102 revenue cycle leaders, puts denials and appeals as the industry’s single largest concern — ahead of staffing shortages and audit activity. The finding lands alongside two market-level pressures pushing collections down even as denial management improves: rising payer clawbacks and deteriorating self-pay performance as patient out-of-pocket costs increase under 2027 plan designs.
| KPI | Industry Average (2026) | Target | Action Threshold |
|---|---|---|---|
| Initial denial rate | 10–12% | Below 5% | Above 10% |
| Days in A/R | 35–45 days | Under 40 days | Above 50 days |
| Net collection rate | 92–95% | 95%+ | Below 90% |
| Clean claim rate | 92–94% | 95%+ | Below 90% |
| Cost to collect | 3.5–5% | Under 3% | Above 6% |
HFMA’s October–November 2026 issue highlights a growing concern: practices deploying patient-facing technology (payment plans, digital statements, cost estimators) are finding it harder to justify those investments purely on short-term financial returns. As 2027 MA plans carry higher maximum out-of-pocket limits and Part D deductibles rise ~30% on average for some plans, the amount patients owe per encounter is rising, but their ability and willingness to pay is not rising proportionally.
The practical response: a pre-service financial clearance workflow that identifies patients with high expected out-of-pocket before the visit and coordinates a payment plan or financial assistance discussion at check-in. Collect $50 before the encounter and document a plan for the rest — rather than chasing a $400 copay in collections 90 days later.
The difference between a 93% and a 96% net collection rate on a $3 million annual revenue base is $90,000. For most independent practices, that gap is closed not by a new vendor but by fixing three or four specific process failures: claims not submitted within 24 hours, self-pay accounts not touched within 30 days, and secondary claims not filed when primary pays. Run that audit before looking at new technology.
The technology story of the quarter in RCM is the convergence of platform consolidation and agentic AI — and Waystar is at the center of both. Its $1.25 billion acquisition of Iodine Software (an AI-driven clinical documentation and coding platform) closes the loop between the claim and the clinical note in a single vendor stack. And its August 2026 AltitudeAI agentic launch signals that the next generation of RCM automation doesn’t just flag a problem — it resolves it.
Iodine Software’s core product is a clinical AI engine that reads medical records and suggests the most accurate diagnosis codes and documentation flags. Where Waystar previously lived on the billing side of the encounter (claim scrubbing, denial management, payment posting), Iodine adds upstream value at coding and documentation. For practices using Waystar, the Iodine integration means a single vendor now spans documentation support, coding suggestion, claim scrubbing, and denial resolution.
The KLAS “A” rating is notable not just because Waystar received it, but because KLAS awarded it in the first-ever evaluation of RCM suites — organizations using at least three RCM solutions from one vendor. The category’s existence reflects the market’s movement away from best-of-breed point solutions and toward consolidated platforms with fewer integration seams.
Waystar’s August 26, 2026 AltitudeAI launch described agentic capabilities that autonomously resolve claims: the agent reads the EOB denial reason, pulls relevant clinical documentation, constructs the appeal package, submits it, and logs the result. The claim review engine analyzes up to 30,000 data points per record. Waystar reports a projected 25% reduction in clinical documentation review time.
| Automation Tier | What It Does | Waystar’s Answer |
|---|---|---|
| Gen AI | Appeal letters, PA packets, documentation drafts | AltitudeAI generative layer |
| AI/ML | Coding accuracy, denial prediction, underpayment flags | Iodine engine (post-acquisition) |
| Agentic / RPA | Autonomous claim resolution, eligibility, payment posting | AltitudeAI agentic workflows |
A practice evaluating RCM technology consolidation in 2026 should ask three questions: (1) Does the vendor’s AI access my clinical note, or only my claim? (2) Does the agentic component take a defined action, or does it just surface a recommendation? (3) Who owns the outcome when the agent is wrong? The Iodine acquisition answers question 1 for Waystar clients, but questions 2 and 3 are still being answered across the market.
The Transparency in Coverage Final Rule (CMS 9882-F), released October 5, 2026, is primarily a payer compliance requirement — but it creates audit risk and negotiation leverage for provider organizations that understand it. The rule takes effect December 5, 2026, 57 days from today.
| Requirement | Timeline |
|---|---|
| Switch to quarterly MRF reporting | December 5, 2026 |
| Post plain-text root file linking to MRF location | December 5, 2026 |
| Executive attestation on data accuracy | December 5, 2026 |
| Expand out-of-network pricing data | Phased through 2027 |
| Develop Prescription Drug File schema | CMS begins November 2026 |
Once accurate quarterly files are available:
The October 8 MLN Connects edition reminded all providers using an EHR, practice management system, or EDI clearinghouse to confirm their HETTS EDI Enrollment email address by December 1, 2026. HETTS is the CMS gateway for electronic Medicare correspondence. A missing or outdated address means your practice will not receive electronic notifications from Medicare about claim changes, audit requests, or contractor communications.
OIG’s active work plan includes a review of CMS’s oversight of hospital price transparency compliance. Practices with a hospital outpatient department component should verify their standard charge files are current, accessible, and formatted per CMS requirements before year-end. Enforcement activity — written warnings, corrective action plans, and civil monetary penalties up to $45,000 per day for large facilities — is active now.
The financial pressure on independent practices in 2026 is structural, not cyclical — and a new Veradigm survey puts numbers on it. But the 2027 proposed fee schedule contains a rarely acknowledged offset that specifically favors independent, office-based practices.
| KPI | Independent Practice Typical Range | Target | Priority Action |
|---|---|---|---|
| Days in A/R | 38–55 days | Under 40 days | Prioritize claims >30 days with commercial payers |
| Net collection rate | 89–93% | 95%+ | Run 90-day self-pay audit; close gaps on secondary claims |
| Prior auth turnaround | 4–9 business days | 72 hours (federal standard) | Verify which payers are meeting the January 2026 rule |
| Clean claim rate | 88–93% | 95%+ | Encoder/scrubber tune-up post October 1 code set |
| Revenue leakage visibility | Low (24% have clear visibility) | Full visibility | Map top 5 CPT codes by denial root cause monthly |
Veradigm’s March 2026 survey found that 94% of independent practices report being approached about acquisition or consolidation in the past two years. Of those, 26% advanced to serious negotiations before choosing to remain independent. The most significant threats: increased operating costs, administrative and regulatory burden, and reimbursement pressure. Only 24% of practices report clear visibility into where revenue leaks — a foundational gap that makes financial comparisons with acquiring entities difficult.
For practices with more than 40 clinicians, the strain is highest: 82% report increased financial pressure, and the administrative-to-clinical staff ratio approaches that of health system-employed practices without the corresponding infrastructure investment.
The proposed 2027 fee schedule estimates that its methodology changes would increase Medicare payments for services delivered in independent office-based settings by approximately 4%, while decreasing payments for the same services in facility-based (outpatient hospital or HOD) settings by approximately 7%. This reflects CMS’s ongoing effort to reduce the facility differential that has made hospital employment of physicians economically attractive. The final rule lands in November — confirm whether this offset survives before revising your budget.
Independence has a material financial value in 2027 if the fee schedule adjustment survives the final rule. The question is whether that value is visible on your P&L — and whether your revenue cycle operations are clean enough to capture it. A practice with a 92% net collection rate on a $3M base loses $90,000 annually compared to a practice at 95%. Fixing that gap is worth more than the site-of-service differential alone.
| Specialty | Key Update This Week | Data Point | What to Do |
|---|---|---|---|
| Primary Care | G2211 complexity add-on converts to modifier in 2027 proposed rule; wait for November final rule before updating encoder | Proposed at 16% of billed E/M value | Confirm encoder vendor’s plan for G2211 modifier transition; do not change workflows until final rule |
| Cardiology | UHC removed PA on cardiac imaging and interventional procedures October 1; review October remits for auth-related denials that should now be resolved | AR days median: 39.4; denial rate: 12.7% | Pull October 1+ cardiac claims; verify PA-free codes on UHC’s official code list — not the summary |
| Orthopedics | NCCI v32.3 quarterly update affects surgical code pairs; verify bundling edits for procedures in your OR schedule | Clean claim rate benchmark: 95.4% | Run NCCI check on top 20 surgical CPT pairs using the October 1 edit file |
| Oncology | Aetna cancer auth bundle expanding to Medicare & commercial in H1 2027; GLOBE model starts January 1 for in-scope drugs; 83 days to go | Denial rate median: 13.8%; AR days: 45.2 | Map which drugs you infuse that are in scope for GLOBE; identify patient ZIP codes in GLOBE geographic areas |
| Mental Health | Medicare telehealth flexibilities (audio-only, originating-site waiver) extended through December 31, 2027 by Consolidated Appropriations Act, 2026 | Tele-mental health ~38% of mental health visits in 2025 (SAMHSA) | Confirm telehealth consent and billing workflows are current; document modality (audio vs. video) on every encounter |
| Neurology | New FY 2027 ICD-10-CM codes improve specificity for stroke subtypes, epilepsy monitoring, and hereditary neurological syndromes; old codes may trigger payer edits | ~60 new codes in Chapter 19 (injury/poisoning) affecting trauma neurology | Audit stroke, TIA, and seizure diagnoses submitted after October 1 for specificity compliance |
| Radiology | DMEPOS fee schedule quarterly update effective October 1 includes imaging-adjacent equipment codes; NCCI MUE update affects outpatient imaging unit limits | October HCPCS quarterly drug & supply code update also effective | Cross-check imaging CPT units against the October 1 MUE table; verify equipment codes match updated allowables |
| Gastroenterology | New Lynch syndrome ICD-10-CM codes (replacing unspecified genetic susceptibility code) affect GI colonoscopy and genetic counseling billing | New specific codes for Lynch syndrome, familial adenomatous polyposis in FY 2027 set | Update ICD-10 mapping for Lynch syndrome in EHR problem lists; review Lynch-associated colonoscopy claims after October 1 |